University of Glasgow

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

How liberal conspiracy theories can be just as destructive as their extremist counterparts

Retrieved on: 
Monday, January 8, 2024
Trump, Policy, CNN, University of Glasgow, Community, Public opinion, Conspiracy theory, Fear, Racism, Spanish–American War, Government, Research, Al Jazeera, Prevalence, Weapon, Black, QAnon, History, Labour Party, Corruption, COVID-19, Black Lives Matter, RT, Bad News, Anthony Scaramucci, Socialism, Unemployment, Overalls, Time, Politics, MSNBC

Liberal commentators frequently condemn conspiracy theories that threaten public safety.

Key Points: 
  • Liberal commentators frequently condemn conspiracy theories that threaten public safety.
  • But what if liberal conspiracy theories can be even more wrong-headed and damaging than their fringe counterparts?

Conspiracy theories, right and left

  • Liberal observers often present conspiracism as the preserve of right or left-wingers.
  • Journalist David Aaronovitch and philosopher Quassim Cassam, for example, attribute fallacious conspiracy theorising to the political “extremes”.
  • According to academic Grażyna Piechota, RT is guilty of “building a conspiracy message [and] using it as a political instrument”.

Combating Corbyn

  • But this didn’t stop exaggerated and indeed conspiratorial antisemitism allegations emerging from the British political centre in the mid-2010s to discredit then-Labour party leader Jeremy Corbyn and his supporters.
  • Sacks went further by likening Corbyn to the infamous racist politician Enoch Powell.
  • Corbyn himself repeatedly denied accusations of institutional antisemitism in the party but was suspended for claiming that such charges were “dramatically overstated for political reasons”.
  • Leaked documents from within Labour and an Al Jazeera investigative report found that antisemitism had been “weaponised” against Corbyn by his adversaries.

Trying to topple Trump

  • There were even claims about Trump cavorting with Russian prostitutes in a Moscow hotel room.
  • These liberal conspiracy theories about Trump and Corbyn are as simplistic and fallacious as much leftist and rightist conspiracism because they too often ignore wider economic and political contexts.

Deadly dangers of liberal conspiracism

  • Conspiracism from the centre can also have deadly consequences.
  • For instance, the 2003 invasion of Iraq, described by US intellectual Noam Chomsky as “the worst crime of the 21st century”, was justified by western governments’ false claim that Saddam Hussein could deploy deadly weapons within 45 minutes.


Stephen Harper is affiliated with the Socialist Party of Great Britain. Tom Sykes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Monday, January 8, 2024
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, European Commission, Food, HRR, Risk, Movement, Prognosis, PFE, Confidence interval, Disease, Prostate cancer, Doctor of Philosophy, Civil service commission, Cancer, University, PARP, Death, Clinical Cancer Research, University of Glasgow, ADP, Talazoparib, Patient, Safety, Medicine, Inc., Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
  • With this approval, TALZENNA is now the first and only PARP inhibitor licensed in the European Union for use with XTANDI for patients with mCRPC, with or without gene mutations.
  • “The European Commission’s approval of talazoparib in combination with enzalutamide offers a meaningful advancement for the treatment of patients with metastatic castration-resistant prostate cancer, the most advanced and aggressive stage of the disease.”
    “After years of fighting prostate cancer, it can be devastating for a patient to learn that their cancer has stopped responding to testosterone-lowering treatments.
  • At this stage of the disease, the prognosis is generally poor,” said Erik Briers, MS, PhD, Vice Chairman, Europa UOMO, a European advocacy movement for people with prostate cancer.

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria

Retrieved on: 
Tuesday, November 14, 2023
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Investment, Therapy, Gram, Patient, Medicine, University of Strathclyde, Death, University of Oxford, Laboratory, Klebsiella pneumoniae, GSK, Bacteria, Collateral damage, AMR, Klebsiella, University, Pseudomonas aeruginosa, University of Glasgow, Innovation, Physician, Scottish Enterprise, Pharmaceutical industry, Antibiotics, Entrepreneurship, Bacteriocin

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Key Points: 
  • Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
  • **
    Glox Therapeutics is developing precision antibiotics utilising engineered protein bacteriocins.
  • Leveraging the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics.
  • “This seed funding is testament to the promise of Glox Therapeutics’ precise antibiotic therapies, and we are thrilled to have the backing of such high-calibre investors.

First and Oldest Non-Profit in Illinois, the Chicago Scots, Will Transform Elder Care with Huge $14m Gift

Retrieved on: 
Wednesday, December 6, 2023
Organization, University of Glasgow, Social isolation, Risk, Long-term care, Obesity, Friends, National academy, Ageing, Family, Museum, Smoking, Management, Nursing, Science

CHICAGO, Dec. 6, 2023 /PRNewswire/ -- The Chicago Scots, Illinois' first and oldest non-profit organization, has received a foundational $14 million gift from The Negaunee Foundation to launch a program to meet the future unmet needs of Chicago's senior population.

Key Points: 
  • They will want to live collaboratively in community with others, to be connected and not isolated, to be social and not lonely.
  • The Negaunee Foundation's incredible gift will empower us to relieve distress caused by aging – medical, cognitive, and social."
  • "Chicago Scots will realign its mission to provide for future unmet needs of seniors in Chicago," said Charles Gonzalez, Chair of the Chicago Scots Board of Governors.
  • "Time and again throughout their long history, Chicago Scots have positioned and repositioned themselves to be relevant in the field of care.

Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

Retrieved on: 
Thursday, October 5, 2023
Interest, Division, School, Circulatory system, Hypertrophic cardiomyopathy, UCSF, FACC, University of Glasgow, University, University of California, Doctor of Philosophy, Heart failure, Heart failure with preserved ejection fraction, SAN, Cytokinetics, Patient, Pharmaceutical industry, Cardiology, HCM

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET.
  • Interested parties must register online at https://cytokinetics-new-horizons-in-hypercontractility.open-exchange.net/ .
  • Registered attendees may access the virtual event platform by visiting the Investor & Media section of the Cytokinetics website at www.cytokinetics.com .
  • A link to the webcast replay will be archived on the Cytokinetics website until April 19, 2024.

EnLiSense CCM To Advance IBD Care with Innovative Sweat Sensor Studies, Teams Up with Leading Clinicians

Retrieved on: 
Wednesday, October 4, 2023
Technology, Biotechnology, Health, Other Health, Professional Services, Research, Medical Devices, Software, General Health, Data Analytics, Genetics, Health Technology, Science, Data Management, Brain-derived neurotrophic factor, University, Crohn's & Colitis Foundation, GFAP, IBD, University of Texas at Austin, Melatonin, Interleukin 6, Biomarker, Glial fibrillary acidic protein, IL6, University of Glasgow, Crohn's disease, Patient, CRP, Physician, Conditional sentence, Inflammatory bowel disease, BDNF, Glucose, Skin, C-reactive protein, Pharmaceutical industry, Medical imaging, Cortisol, Calprotectin, CCM

Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.

Key Points: 
  • Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
  • The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat.
  • This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
  • Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging.

 Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ENAD Ayiou Dometiou FC, Radiation, University, Therapy, Function, Bio, Cancer Research UK, University college, Research fellow, Antibody, Radiation therapy, Cancer Science, University of Glasgow, MRI, Date, Primary tumor, Transgene, Patient, Monochorionic twins, Master of Science, School, Chemokine, Cytokine, Society, Vaccine, Medical imaging, Safety, Chemoradiotherapy

In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.

Key Points: 
  • In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.
  • Further, hexon staining of patient samples suggested EnAd localization in both the primary tumor and in metastatic sites.
  • “These data are compelling given the higher-than-expected pCR/cCR rate, and the low adverse event rate highlights the ability to deliver the oncolytic virus concurrently with chemoradiation.
  • ET
    Presenter: Dr Séan M. O’Cathail, MSc DPhil MRCPI FRCP FRCR, Senior Research Fellow, School of Cancer Sciences, University of Glasgow

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Retrieved on: 
Friday, September 1, 2023
AME Publishing Company, Lead, University, Medivir, Clifton Springs Hospital & Clinic, Cancer, DRS, Reig, Oncology, BCLC, Research, CMO, Cancer Science, Defence Scientific Advisory Council, ECMC, University of Glasgow, Liver cancer, Patient, School, Dr. Evan Alexander Erwin House, Webcast, Hospital, HCC, Lenvatinib, Disease, Pharmaceutical industry, Medical device, Beatson West of Scotland Cancer Centre

The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.

Key Points: 
  • The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.
  • He will be joined by Dr. Maria Reig, Liver Cancer Unit, Hospital Clínic BCLC group, Villarroel, Barcelona, Spain, who will discuss how HCC is different from many other tumor types and its unique treatment challenges.
  • Both Drs are investigators in the phase 1b/2a study with fostrox in combination with Lenvima and will also share their perspectives from the ongoing study.
  • The webcast will be streamed via a link on the website: www.medivir.com/investors/presentations The presentation will be available on Medivir´s website after the webcast.